Blood Res.  2023 Dec;58(4):234-237. 10.5045/br.2023.2023182.

Ibrutinib combined with gemcitabine-vinorelbine for primary refractory non-Hodgkin lymphoma

• Aydin MS
• Cengiz E
• Can F
• Dagdas S
• Dilek I
• Ozet G

• KMID: 2550204
• DOI: http://doi.org/10.5045/br.2023.2023182

Reference

1. Kesireddy M, Lunning M. 2022; Relapsed or refractory diffuse large B-cell lymphoma: "Dazed and Confused". Oncology (Williston Park). 36:366–75.

2. Skrabek P, Assouline S, Christofides A, et al. 2019; Emerging therapies for the treatment of relapsed or refractory diffuse large B cell lymphoma. Curr Oncol. 26:253–65. DOI: 10.3747/co.26.5421. PMID: 31548805. PMCID: PMC6726277.

3. Mamgain G, Singh PK, Patra P, Naithani M, Nath UK. 2022; Diffuse large B-cell lymphoma and new insights into its pathobiology and implication in treatment. J Family Med Prim Care. 11:4151–8. DOI: 10.4103/jfmpc.jfmpc_2432_21. PMID: 36353039. PMCID: PMC9638643. PMID: 6e3b0a3a799f4d51b24acf65334cb6b5.

4. Hou K, Yu Z, Jia Y, et al. 2020; Efficacy and safety of ibrutinib in diffuse large B-cell lymphoma: a single-arm meta-analysis. Crit Rev Oncol Hematol. 152:103010. DOI: 10.1016/j.critrevonc.2020.103010. PMID: 32540781.

5. Petrackova A, Turcsanyi P, Papajik T, Kriegova E. 2021; Revisiting Richter transformation in the era of novel CLL agents. Blood Rev. 49:100824. DOI: 10.1016/j.blre.2021.100824. PMID: 33775465.

6. Thompson PA, Siddiqi T. 2022; Treatment of Richter's syndrome. Hematology Am Soc Hematol Educ Program. 2022:329–36. DOI: 10.1182/hematology.2022000345. PMID: 36485138. PMCID: PMC9820569.

7. Zhou Z, Zhang L, Wang X, et al. 2021; Ibrutinib combined with venetoclax for the treatment of relapsed/refractory diffuse large B cell lymphoma. Ann Hematol. 100:1509–16. DOI: 10.1007/s00277-021-04535-7. PMID: 33900450.

8. Wilson WH, Phillips T, Popplewell L, et al. 2021; Phase 1b/2 study of ibrutinib and lenalidomide with dose-adjusted EPOCH-R in patients with relapsed/refractory diffuse large B-cell lymphoma. Leuk Lymphoma. 62:2094–106. DOI: 10.1080/10428194.2021.1907371. PMID: 33856277. PMCID: PMC9907362.

9. Kuruvilla J, Crump M, Villa D, et al. 2017; Canadian Cancer Trials Group (CCTG) LY.17: a randomized phase II study evaluating novel salvage therapy pre-autologous stem cell transplant (ASCT) in relapsed/refractory diffuse large B cell lymphoma (RR-DLBCL) - outcome of ibrutinib + R-GDP. Hematol Oncol. 35:88. DOI: 10.1002/hon.2437_76.

10. Kedmi M, Ribakovsy E, Benjamini O, et al. 2018; Ibrutinib, bendamustine, rituximab combination for relapsed and refractory aggressive B cell lymphoma - interim analysis of phase II clinical trial. Blood (ASH Annual Meeting Abstracts). 132(Suppl):4186. DOI: 10.1182/blood-2018-99-111658.

11. Maddocks K, Christian B, Jaglowski S, et al. 2015; A phase 1/1b study of rituximab, bendamustine, and ibrutinib in patients with untreated and relapsed/refractory non-Hodgkin lymphoma. Blood. 125:242–8. DOI: 10.1182/blood-2014-08-597914. PMID: 25355819.

12. Sauter CS, Matasar MJ, Schoder H, et al. 2018; A phase 1 study of ibrutinib in combination with R-ICE in patients with relapsed or primary refractory DLBCL. Blood. 131:1805–8. DOI: 10.1182/blood-2017-08-802561. PMID: 29386196. PMCID: PMC5909762.

13. Sivam V, Cook L, Hughes G, et al. 2012; Gemcitabine and vinorelbine chemotherapy for refractory or relapsing aggressive non- Hodgkin lymphoma. Hematol Oncol. 30:214–5. DOI: 10.1002/hon.2011. PMID: 22422565.